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Abstract.  Thrombospondin  induces the migration of 
human melanoma and carcinoma cells.  Using a 
modified Boyden chamber assay,  tumor cells migrated 
to a  gradient of soluble thrombospondin (chemotaxis). 
Checkerboard analysis indicated that directional migra- 
tion was induced 27-fold greater than  stimulation of 
random motility.  Tumor cells also migrated in a dose- 
dependent manner to a gradient of substratum-bound 
thrombospondin (haptotaxis).  A  series of human mela- 
noma and carcinoma cells were compared for their 
relative motility stimulation by thrombospondin hap- 
totaxis vs.  chemotaxis.  Some cell lines exhibited a 
stronger haptotactic response compared to their 
chemotactic response while other lines exhibited little 
or no migration  response to thrombospondin.  Human 
A2058 melanoma cells which exhibit a  strong hap- 
totactic and chemotactic response to thrombospondin 
were used to study the structural domains of throm- 
bospondin required for the response.  Monoclonal anti- 
body C6.7,  which binds to the COOH-terminal  region 
of thrombospondin,  inhibited haptotaxis  in a dose- 
dependent optimal manner.  C6.7  had no significant 
effect on thrombospondin chemotaxis.  In contrast, 
monoclonal antibody A2.5, heparin,  and fucoidan, 
which bind to the NH2-terminal heparin-binding  do- 
main of thrombospondin,  inhibited thrombospondin 
chemotaxis but not haptotaxis.  Monoclonal antibody 
A6.1 directed against the internal  core region of throm- 
bospondin had no significant effect on haptotaxis or 
chemotaxis.  Synthetic peptides GRGDS (50 p.g/ml), 
but not GRGES, blocked tumor cell haptotaxis on 
fibronectin, but had minimal effect on thrombospondin 
or laminin haptotaxis.  The  140-kD fragment of throm- 
bospondin lacking the heparin-binding  amino-terminal 
region retained the property to fully mediate haptotaxis 
but not chemotaxis.  When the COOH region of the 
140-kD fragment,  containing  the C6.7-binding  site,  was 
cleaved off, the resulting  120-kD fragment (which re- 
tains the RGDA sequence) failed to induce haptotaxis. 
Separate structural domains of thrombospondin are 
therefore required for tumor cell haptotaxis vs. 
chemotaxis.  This may have implications during hema- 
togenous cancer metastases formation. 
T  HROMBOSPONDIN is  a  multifunctional  glycoprotein 
first  described as  a  secretion product of thrombin- 
stimulated platelets (2). Thrombospondin is a compo- 
nent of the extracellular  matrix  in a wide variety of tissues. 
By immunohistology,  thrombospondin is localized  in base- 
ment membranes,  vessel walls, and interstitium (32). Throm- 
bospondin  is  also  secreted by  several  cultured  cell  lines 
including endothelial,  smooth muscle cells, fibroblasts, pneu- 
mocytes, macrophages,  monocytes, and tumor cells (ll,  12, 
14,  17, 24, 26). 
Like fibronectin  and laminin,  thrombospondin binds to a 
diverse array of macromolecules and mediates cell adhesion 
in vitro (5, 6, 14, 15, 21-24, 31). Based on activities ofproteo- 
lytic fragments  and using  ligands and antibodies  to throm- 
bospondin to inhibit  adherence,  at least two regions  of the 
molecule are involved in attachment  and spreading of human 
G361 melanoma cells on surfaces coated with thrombospon- 
din (23). The monoclonal antibody A2.5 directed against the 
heparin-binding  domain of thrombospondin (8, 9) selective- 
ly inhibits melanoma spreading  but only weakly inhibits at- 
tachment.  Large fragments  of thrombospondin lacking  the 
heparin-binding  domain support attachment  but not spread- 
ing of G361 ceils, and this activity is lost after removal of 
the  18-kD carboxyl-terminal  domain.  The heparin-binding 
domain of thrombospondin recognizes cell surface sulfatides 
and other sulfated glycoconjugates  which may serve as re- 
ceptors distinct from those which recognize the carboxyl ter- 
minus  of thrombospondin (15, 23, 26-28, 33). 
Tumor  invasion  and  metastases  is  a  multistep  process 
which requires active tumor cell migration through extracel- 
lular matrix barriers (16). Circulating  tumor cells can poten- 
tially interact  with  thrombospondin during  the process of 
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lets, migrate underneath endothelial cells, and traverse the 
subendothelial basement membrane (16). All of these sur- 
faces may be rich in thrombospondin. Although thrombo- 
spondin is known to play a role in cell attachment and growth 
(17, 23, 31), little is known concerning its role in tumor cell 
locomotion. The present study was performed to compare 
the promotion of tumor cell migration by substrate-bound 
(haptotaxis) vs. soluble thrombospondin (chemotaxis). The 
results indicate that separate domains of thrombospondin are 
involved in haptotaxis vs. chemotaxis of human tumor cells. 
Materials and Methods 
Calcium-replete  thrombospondin was  purified  from  the  supernatant  of 
thrombin-stimulated human platelets by affinity chromatography on gela- 
tin-agarose and heparin-agarose and gel filtration on Bio-gel A0.5m (10). 
The purified protein migrated as a single band (M, 180,000) on electropho- 
resis in the presence of SDS and 2-mereaptoethanol (13) and was stored at 
-70~  in Tris-buffered saline, pH 7.6, containing 20% sucrose and 0.1 mM 
CaCI2.  Synthetic peptides corresponding to the cell-attachment site for 
fibronectin (GRGDS and the control GRGES) were provided by Dr. Ken- 
neth M. Yamada (National Cancer Institute, National Institutes of Health, 
Bethesda, MD). Monoclonal antibodies to thrombospondin were provided 
by Dr.  William Frazier (Washington University School of Medicine, St. 
Louis, MO). Laminin was purified from Engelbreth-Holm swarm (EHS) tu- 
mor as described (29). Fibronectin and type IV collagen were purchased 
from Collaborative Research (Bedford, MA) or Gibco (Grand Island, NY). 
Cell Lines 
A2058 human melanoma (30),  MDA-MB-361  human breast adenocarci- 
noma (ATCC  HTB 27),  MDA-MB-435S human breast ductal carcinoma 
(ATCC HTB 129), and Hs578 Bst human breast-immortalized myoepithe- 
lial cells (ATCC  HTB  125) were maintained in culture in DME supple- 
mented with 10% FCS. Human melanoma cell lines C32 (ATCC CRL 1585) 
and G361 (ATCC CRL 1424) were maintained in vitro in RPMI 1640 con- 
taining 10% FCS. Media and serum were provided by Meloy Laboratories, 
Inc. (Springfield, VA) or Gibco. 
Limited Proteolysis of Thrombospondin 
Thrombospondin was digested with 4 U/nil reagent thrumbin (provided by 
Dr. Jules Gladner, NIH) in 20 mM Tris-buffered saline, pH 7.6, containing 
0.1 mM or2 mM CaC12, for 16 h at 37~  or with trypsin, chymotrypsin 
(0.5 % wt/wt), or thermolysin (1:100 wt/wt) as described previously (10, 23). 
The digestions were stopped by addition of 2  mM phenylmethylsulfonyl 
fluoride (PMSF) and the cleavage products were fractionated by chromatog- 
raphy on heparin-agarose (8, 9, 23).  The fragments were judged pure by 
electrophoresis in the presence of SDS and 2-mercaptoethanol as shown 
previously (23, 26-28) and tested for chemotactic and haptotactic activities. 
Cell Motility Assays 
Chemotaxis and haptotaxis were assayed using modified Boyden chambers, 
with 8-gm pore size polycarbonate Nucleopore filters. 
For haptotaxis, filters were coated on one side by floating them overnight 
at 37~  on a solution of thrombospondin (20 Ixg/ml), in Dulbecco's PBS or 
laminin or fibronectin (10 gg/ml in 50 mM carbonate buffer,  pH 9.6).  The 
coating method used was identical to that described by McCarthy et al. (20). 
Chambers were then assembled with serum-free medium containing 0.1% 
BSA. The side of the filter with the highest concentration of protein faced 
the lower compartment. 
For chemotaxis, filters were soaked overnight at 37~  in Dulbecco's PBS. 
To test thrombospondin-mediated  chemotaxis on different substrates, filters 
were soaked overnight in solutions of laminin (10 gg/ml in 50 mM carbonate 
buffer, pH 9.6), type IV collagen (40 Ixg/ml in 0.1 M acetic acid), or gelatin 
(100 Ixg/ml in 0.1% acetic acid). All filters were washed five times in Dul- 
becco's PBS before use. Chemotaxis was conducted as described previously 
(19, 25). 
Cells in logarithmic phase of growth were detached by brief exposure to 
0.05%  trypsin/0.02% EDTA and kept 1 h in serum-containing medium be- 
fore the assay. The upper compartment of the chamber was then filled with 
4  x  105 cells in serum-free medium supplemented with 0.1% BSA. After 
a 4-5-h incubation at 37"C filters were stained with Diff Quick (American 
Scientific Products, MacGraw Park,  IL) and the amount of the migrated 
cells was measured with a 2202 Ultroscan Laser Densitometer (LKB Instru- 
ments, Gaithersburg, MD). We found a linear correlation (r  =  0.99) be- 
tween the number of migrated cells counted per high power field (50x) and 
the optical density area units. 
The effect of antibodies and thrombospondin-binding molecules, hepa- 
rin, and fucoidan on motility was assayed by adding them in the lower com- 
partment of the chamber with the thrombospondin for chemotaxis. For hap- 
totaxis the antibodies or polysaccharides were added to either the top 
or the bottom of the modified Boyden chamber. 
Results 
Thrombospondin-induced Chemotaxis 
Thrombospondin stimulated the migration of human mela- 
noma cells in the modified Boyden chamber assay (Fig.  1). 
When a series of thrombospondin concentrations was intro- 
duced into the lower chamber, migration was stimulated in 
a  dose-dependent  manner.  An  increase  in  migration  oc- 
curred within a range of 1.0-150 nM and reached a plateau 
at thrombospondin concentrations higher than this. Checker- 
board analysis was performed to investigate the random or 
directed  nature  of  the  tumor  cell  migration  response  to 
thrombospondin (Fig. 2). In this assay, the migration of tu- 
mor cells was studied using different ratios of thrombospon- 
din above and below the filter.  The squares below the di- 
agonal  reflect  a  positive  gradient,  while  those  above  the 
diagonal reflect a negative gradient. The values along the di- 
agonal indicate random motility to a uniform concentration 
of soluble thrombospondin added to both sides of the cham- 
ber. The checkerboard analysis indicated that migration was 
directional in nature occurring to the highest level in a posi- 
tive gradient (maximum of 27-fold increase) and greatly in- 
hibited in a negative gradient (squares above diagonal). Ran- 
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Figure 1. Dose-response curve for chemotactic response of A2058 
melanoma cells to thrombospondin. Increasing concentrations of 
thrombospondin were added to the lower chamber, diluted in DME, 
supplemented with 0.1% BSA, in a volume of 42 gl. The chambers 
were then assembled with filters (preincubated overnight in Dul- 
becco's PBS and washed); 4  x  105 cells in DME,  supplemented 
with 0.1% BSA were added, and the incubation time was 4  h. Data 
are expressed as mean number +  SEM of migrated cells per high 
power field, as measured with the Ultroscan Densitometer. 
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Figure 2.  Checkerboard  analysis  of the  chemotactic  activity  of 
thrombospondin. A2058 melanoma cells were tested for chemotac- 
tic response to soluble thrombospondin in presence of different gra- 
dients (positive, negative, or null).  The data shown are the mean 
number of migrated cells as in Fig.  1. 
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Figure 3. Dose-response relationship in the haptotactic response of 
G361 melanoma cells to thrombospondin.  Filters were coated with 
a step gradient  of increasing concentrations  of thrombospondin. 
Data are expressed  as mean  __  SEM of migrated cells per high 
power field. 
dom migration was slightly increased (maximum of twofold 
increase; lower right along the diagonal). 
The effect of substratum composition on thrombospondin- 
mediated chemotaxis was  studied  by coating  the polycar- 
bonate filters with  a  uniform concentration  of laminin or 
proteins that do not significantly bind thrombospondin. Un- 
coated  filters,  laminin,  type  IV  collagen,  and  gelatin  all 
mediated cell adhesion and  served as a  migration surface 
which allowed the cells to sense and respond to the gradient 
of soluble thrombospondin in the fluid phase (Table I). When 
the filters were coated with BSA which failed to mediate tu- 
mor cell adhesion,  no chemotaxis was observed. 
Thrombospondin-induced Haptotaxis 
Tumor cells migrated over substratum-bound thrombospon- 
din in the absence of soluble thrombospondin. The migration 
of cells to a substratum-bound attractant, termed haptotaxis, 
was pronounced in the presence of a step density gradient of 
substratum-bound thrombospondin. When the magnitude of 
the gradient was increased from 0:0 to 0:100 nM, the level 
of haptotaxis increased and began to reach a plateau above 
60 nM (Fig. 3). Only a very low level of random migration 
was observed for filters precoated on both sides with uniform 
concentrations of thrombospondin. 
Table L Thrombospondin-induced Chemotaxis 
on Different Substrates 
Migrated cells*  Attachment 
89.0  +  46.2  + 
Laminin  29.5  +  8.1  + 
Type IV collagen  79.0  +  7.1  + 
Gelatin  45.3  +  8.4  + 
BSA  0  - 
Filters were coated with substrates as described in Materials and Methods. 
Chemotactic test was performed using a solution of 50 p.g/ml thrombospondin 
in DME supplemented with 0.1%  BSA. A2058 melanoma cells were used in 
this assay.  Data are expressed as directed motility, obtained by  subtracting 
nonstimulated motility from total migration. 
* Mean number of cells __.  SEM. 
Heterogeneity of Thrombospondin-mediated 
Chemotaxis and Haptotaxis by Different Human 
Tumor Cell Lines 
A series of human melanoma and breast carcinoma cell lines 
were compared for their migration response to a soluble or 
solid phase gradient of thrombospondin. As shown in Table 
II, six separate human tumor cell lines exhibited wide differ- 
ences in their relative migration induced by thrombospon- 
din.  Two of three  melanoma lines  (A2058  and G361)  ex- 
hibited  both  a  chemotactic  and  a  haptotactic  response to 
thrombospondin. The A2058 melanoma cells showed a simi- 
lar rate of migration by both haptotaxis and chemotaxis. The 
G361 melanoma line demonstrated a greater mean haptotac- 
tic response compared to chemotaxis.  The melanoma line 
C32  was devoid of any  migration response  to  soluble  or 
solid-phase thrombospondin.  The three human breast cell 
lines also differed significantly in their response to throm- 
bospondin-induced migration.  MDA-MB-435S tumor cells 
showed almost no thrombospondin chemotactic response, 
but did respond by haptotaxis. MDA-MB-361 cells failed to 
Table II. Heterogeneity in Thrombospondin-mediated 
Chemotactic and Haptotactic Response by Different Tumor 
Cell Lines 
Spontaneous 
Tumor cell  migration  Chemotaxis*  Haptotaxis* 
A2058  1.75  +  1.2  93.4  -I- 21.0  107.4  -I-  27.6 
G361  0  80.7  +  18.7  153.9  +  38.2 
C32  0  0  0 
MDA435  0  2.4  +  2.4  30.0  +  23.7 
MDA361  0  2.7  +  0.2  0 
HS578  0  62.5  +  22.3  91.5  +  25.6 
The different cell lines were maintained in culture as described in Materials and 
Methods.  The test was performed using their usual culture medium, without 
serum and containing 0.1% BSA. All lines were tested at the same cell concen- 
tration and for the same incubation time (4.5 h).  For haptotaxis, filters were 
coated using a solution of 20 o.g/ml of thrombospondin in Dulbecco's PBS. For 
chemotaxis, 42 rtl of a solution 50 lag/ml thrombospondin in DME was added 
to the lower chamber. 
* Mean number of cells +  SEM. 
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Figure 4.  Haptotactic activity of enzymatic fragments of throm- 
bospondin. Filters were coated overnight on one side with a solu- 
tion of 30 or 15 llg/ml of fragments  in Dulbccco's PBS. Data are 
expressed as percentage of control (undigested thrombospondin). 
(180) Mock-digested  control thrombospondin. (140) 140-kD throm- 
bin generated fragment. (140 4- 120) Equal molar (1:1) ratio of 140- 
and 120-kD fragments. (120) Purified 120-kD chymotrypsin frag- 
ment (devoid of haptotaxis activity). Coating concentrations were 
adjusted for molarity equal to whole thrombospondin. 
respond by either haptotaxis or chemotaxis, whereas Hs578 
Bst cells  migrated toward both types of gradients.  While 
these cell lines differed significantly from one to another, 
they  were  highly  consistent  in  their  response  to  throm- 
bospondin when the same cell line was repeatedly tested. 
These data indicate that different tumor cells regardless of 
their histologic origin may respond to thrombospondin hap- 
totaxis and chemotaxis through different mechanisms and to 
different magnitudes, 
Effect of  Antibodies to Thrombospondin on 
Chemotaxis vs. Haptotaxis 
Affinity-purified  monoclonal antibodies recognizing specific 
domains of thrombospondin were studied for their ability to 
inhibit thrombospondin-mediated haptotaxis or chemotaxis. 
A  striking difference in the antibody specificity was noted 
(Table III). Monoclonal antibody C6.7, which recognizes the 
globular carboxyl terminus of thrombospondin (7, 9), at a 
concentration of 10 ~tg/ml inhibited haptotaxis by 90% (Table 
III).  The inhibition was equally effective if the antibodies 
Table IlL Inhibition of  A2.5 and C6. 7 Monoclonal Antibody 
on Thrombospondin-induced Cell Motility 
Antibody  Concentration  Chemotaxis*  Haptotaxis* 
~g/ml 
C6.7  10  80.8  +_  17.6  10.0  5:  5.0 
I  92.7  +  12.5  63~0  5:11.0 
0.1  85.0  •  18.1  91.5  •  8.5 
A2.5  10  38.0  _+  7.2  90.7  •  21.9 
I  68.7  +  8.2  100.0  +  21.3 
0.1  59.0  +  12.2  95.0  5:  70.0 
A6.1  10  90.6  +  36.4  72.0  •  7.0 
Chemotactic test was performed using a solution of 50 gg/ml thrombospondin 
in DME/0.1%  BSA. Different dilutions of monoclonal antibodies were prein- 
cubated  with TSP for 45  min,  then both were placed  in the lower chamber. 
Haptotaxis was assayed as described', antibodies were added to the lower com- 
partment.  Data are expressed as mean (3-6 experiments) percentage of control 
:1:  SEM. 
* % control  ::k  SEM. 
were added to the top or bottom chamber. The level of hap- 
totactic inhibition decreased proportionally as the C6.7 anti- 
bodies  were diluted.  In contrast to its  inhibition of hap- 
totaxis,  antibody C6.7  had  no  significant dose-dependent 
effect on thrombospondin-induced chemotaxis. Monoclonal 
antibody A2.5,  which  recognizes the amino terminus of 
thrombospondin, exhibited the opposite pattern for haptotac- 
tic vs.  chemotactic inhibition when compared to antibody 
C6.7. Antibody A2.5 inhibited thrombospondin chemotaxis 
in a dose-dependent manner, after a  100-fold difference in 
concentration, but had no significant dose-dependent effect 
on haptotaxis.  Antibody A6.1, which recognizes the core 
70-kD internal domain fragment of thrombospondin (4), did 
not significantly inhibit chemotaxis and only slightly inhibited 
haptotaxis. 
Effect of  Fucoidan, Heparin, and RGD Peptides 
Antibody A2.5 which inhibits chemotaxis but not haptotaxis 
(Table  III) recognizes the heparin-binding amino-terminal 
domain of thrombospondin. This region of thrombospondin 
binds both to sulfated polysaccharides (e.g., heparin), and to 
sulfated glycolipids. Roberts et al. (23) have reported that the 
sulfated fucan, fucoidan, and the monoclonal antibody A2.5 
selectively inhibit melanoma cell spreading, but only weakly 
inhibit attachment. Therefore, the inhibitory effects of hepa- 
rin and fucoidan were studied for thrombospondin-mediated 
tumor cell migration. Heparin and fucoidan both showed an 
inhibition of thrombospondin chemotaxis but had no effect 
on, or in some cases slightly stimulated, haptotaxis (Table 
IV). Considering the very large standard errors, the statisti- 
cal significance of any potential dose-dependent inhibition 
cannot be tested by comparing different doses. Nevertheless, 
in the aggregate these data show some inhibition at all con- 
centrations, most of which are statistically significant. This 
finding is in keeping with a major role for the amino-terminal 
domain in the mediation of chemotaxis but not haptotaxis. 
Thrombospondin contains an RGDA sequence located 241 
amino acid residues from the carboxyl-terminal end of the 
molecule (15). The glycoprotein IIb/IHa complex of  platelets 
has been identified as a receptor which recognizes the RGD 
sequence of fibronectin, fibrinogen, yon Willibrand factor, 
and vitronectin (27).  Parallel studies with thrombospondin 
indicate that this receptor may also bind thrombospondin 
weakly (14, 26),  although platelets lacking IIb/IIIa retain 
normal thrombospondin binding (1). Consequently, the effect 
of purified RGD synthetic peptides were studied for their 
role  in  thrombospondin-mediated haptotaxis.  Fibronectin 
Table IV. Inhibition of Thrombospondin-induced 
Cell Motility 
Inhibitor  Dose  Chemotaxis  Haptotaxis 
Fucoidan 
Heparin 
lz  g  /ml 
100  35.0 + 5.8  146.0 5:9.8 
50  47.0 +  17.1  87.7 5:  16.2 
10  53.0 +  10.7  105.0 5: 63.9 
100  56,3 + 7.6  143.0 5: 21 
50  66.0 5: 7.0  133.3 5: 59,3 
10  59.3 5: 31.3  115.0 5:  19.4 
Data are expressed as mean (3-6 experiments) percentage compared to control 
+  SEM. 
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melanoma cells.  GRGDS at a  concentration of 50  l~g/ml 
abolished fibronectin haptotaxis but GRGES had no effect 
(Table VI).  GRGES at 50 gg/ml had no effect on laminin 
haptotaxis, compared to GRGDS (which slightly stimulated 
laminin haptotaxis) (Table VII). GRGDS and GRGES at a 
concentration of 62.5 ~tg/ml both partially inhibited throm- 
bospondin haptotaxis. At 250 Ilg/ml, GRGDS inhibited 30% 
more than GRGES, a fivefold higher concentration of  GRGDS 
compared with that which inhibited haptotaxis on fibronectin. 
Effect of Thrombospondin Fragments 
Thrombin digestion of thrombospondin in the presence of dif- 
ferent concentrations of Ca  -~ followed by further separation 
on a heparin affinity column yields two classes of fragments. 
The 140-kD fragment contains the COOH-terminal end of 
thrombospondin but lacks the heparin-binding domain resid- 
ing in a region located at the NH2-terminal domain of intact 
thrombospondin (10). The 140-kD fragment can be further 
cleaved  to  a  120-kD  fragment which  lacks  the  COOH- 
binding region for mAb C6.7. Both the 120- and the 140-kD 
fragments have identical amino-terminal sequences (9). The 
thrombospondin fragments were studied for the ability to 
promote tumor cell migration (Fig. 4). The 140- and the 120- 
kD fragments were both devoid of chemotactic activity. In 
contrast, the 140-kD fragment retained full ability to elicit 
haptotaxis with a response equal to or greater than the con- 
trol undigested thrombospondin. When the 140-kD fragment 
was  partially  cleaved  to  the  120-kD  form  (equal  molar 
amounts of 120- and  140-kD  fragments), significant hap- 
totaxis was lost. Furthermore, the fully cleaved 120-kD frag- 
ment was unable to generate a haptotactic response. The 120- 
kD fragment lacks the C6.7-binding site which is retained on 
the  140-kD  fragment.  We  also  studied  the  induction of 
A2058 cell motility by the isolated heparin-binding domain, 
obtained by digestion of thrombospondin with chymotrypsin 
or thermolysin. All the thrombospondin fragments which 
retained the heparin-binding domain induced chemotaxis 
when tested at the same molarity corresponding to 50 ~tg/ml 
of whole thrombospondin. All the fragments failed to induce 
chemotaxis on plain filters, however,  using gelatin-coated 
filters, the heparin-binding fragments obtained by digestion 
with thermolysin induced the same degree of chemotactic re- 
sponse as did whole thrombospondin (106.6% +  45), while 
the  heparin-binding  thermolysin-generated  fragments  in- 
Table V. Effect of GRGDS and GRGES on 
Thrombospondin-induced Haptotaxis on A2058 
Melanoma  Cells 
Dose  Haptotaxis 
GRGDS 
GRGES 
#g/ml 
250  48.5  +  15.5 
125  71.5  +  6,5 
62.5  66.0  +  29.0 
250  80.0  +  15,0 
125  81.5  +  6.5 
62.5  65.0  +  13.0 
Data  are  expressed as  percentage of control  +  SEM,  (Mean of 3-6  ex- 
periments), 
Table VI. Effect of GRGDS and GRGES on 
Fibronectin-mediated Haptotaxis 
Dose  Haptotaxis 
#g/ml 
GRGDS  50  0  (complete inhibition) 
GRGES  50  103,2  +  23,6 
Data  are  expressed as  percentage of control  +  SEM,  (Mean  of 3-6  ex- 
periments). 
duced a twofold chemotactic response (195 % +  12.4) com- 
pared to equal molar quantities of whole thrombospondin. 
All the above heparin-binding fragments were unable to in- 
duce any significant haptotaxis. The thrombospondin frag- 
ment results are consistent with the antibody inhibition data, 
further demonstrating that the heparin-binding amino-termi- 
nal region of thrombospondin is required for chemotaxis, 
whereas the C6.7-binding  COOH-terminal region of throm- 
bospondin is required for haptotaxis. 
Discussion 
Tumor cells encounter a variety of soluble and substratum- 
bound factors which may influence their directed migration 
at  different stages  in  the  process  of tumor  invasion and 
metastases (3, 16, 18). Such factors can promote the directed 
movement of  tumor cells by at least two mechanisms, termed 
chemotaxis and haptotaxis. Chemotaxis refers to the directed 
migration of cells toward a soluble gradient of the attractant. 
The chemoattractant gradient is sensed by the migrating cell 
and influences the direction of locomotion. Haptotaxis, on 
the other hand, refers to the directed migration of cells along 
a gradient of substratum-bound insolubilized attractant. As 
shown in the present report, thrombospondin can induce tu- 
mor cell migration by both chemotaxis and haptotaxis (Figs. 
1-3,  and Table I),  and this requires  separate domains of 
thrombospondin for each type of migration response. In the 
case of chemotaxis, the substratum adhesion factors used by 
the migrating cells may be unrelated to the chemoattractant 
which exists in a soluble form in the fluid phase (25).  This 
is true for leukocytes which respond to the chemoattractant 
FMLP (25).  In this example, attachment to the substratum 
is  required  for  leukocytes to  migrate  toward  FMLP,  but 
FMLP does  not directly mediate adhesion  (25).  Throm- 
bospondin can also  mediate a  true chemotactic response 
which is dependent of the mechanism used for cell-substra- 
tum  attachment.  As  shown  in  Table  I,  thrombospondin 
mediated chemotaxis of melanoma cells  when the  filters 
were coated with a variety of proteins which mediate adher- 
Table VII. Effect of GRGDS and GRGES on 
Laminin-mediated Haptotaxis 
Dose  Haptotaxis 
#g/ml 
GRGDS  50  157.9  +  4.1 
GRGES  50  100,9  +  44.7 
Data  are  expressed as  percentage  of control  +  SEM,  (Mean  of 3-6 ex- 
periments). 
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Figure 5. Thrombospondin  subunit structure related to chemotaxis- 
and haptotaxis-promoting  domains. The thrombospondin  trimer is 
composed of three subunits that are linked by interchain disulfide 
bonds forming a protease-resistant core near the amino-terminal 
globular region. The alignment of proteolytic fragments and anti- 
body-binding  sites are shown and correlated with a differential  hap- 
totactic or chemotactic response. 
ence. In particular, when the filters were coated with gelatin, 
which mediates tumor cell attachment but does not bind 
thrombospondin, a chemotactic response was observed. In 
contrast, when the filters were coated with BSA, which did 
not mediate A2058 melanoma cell attachment and did not 
bind thrombospondin, the tumor cells failed to attach and 
therefore failed to exhibit a chemotactic response. 
Thrombospondin is a  trimer composed of subunits that 
contain a small (8 nm) globular domain, a connecting rod- 
shaped (~20 nm) region, and a larger (17 nm) globular do- 
main (Fig.  5).  The small globular domain represents the 
NH2  terminus  of the  peptide  chain.  Three  subunits  are 
joined along the rod-shaped region at a point ~16 nm from 
the carboxy terminus which represents the large globular do- 
main. The two monoclonal antibodies A2.5 and C6.7, which 
bind to two epitopes at essentially the maximum possible dis- 
tance on the thrombospondin molecule, exhibit a remarkable 
difference in their inhibition of thrombospondin-induced tu- 
mor cell migration. C6.7, which binds to the large globular 
COOH  domain,  blocks  thrombospondin-mediated hapto- 
taxis, but not chemotaxis. A2.5, which binds to the small 
globular NH2 end, inhibits chemotaxis, but not haptotaxis. 
The differential effect strongly suggests  that opposite do- 
mains of thrombospondin are involved in separate types of 
motility responses. 
McCarthy et al. have reported that adhesion and motility 
functions can be separated using fragments of fibronectin 
(19). In the case of thrombospondin, adhesion and motility 
can  also  be  separated.  Furthermore,  chemotaxis  can  be 
mediated by thrombospondin when the cells are migrating on 
a surface coated with adhesion proteins different from throm- 
bospondin (Table I). 
Well-defined  proteolytic  fragments  of  thrombospondin 
have been prepared which retain one or more of its multiple- 
binding  domains  (Fig.  5).  When  native  thrombospondin 
(180-kD) is digested with thrombin, 25- and 140-kD frag- 
ments are generated. The 25-kD fragment is derived from 
the amino terminus (6),  binds to heparin-Sepharose,  and 
contains the binding site for mAb A2.5. Rotary shadowing 
of thrombospondin bound to A2.5 demonstrated that this site 
is in the small globular end region of the thrombospondin 
subunits (9).  Monoclonal antibody C6.7 binds to the large 
globular domain on the opposite end of the thrombospondin 
molecule compared  to  the binding location of A2.5  (9). 
Amino acid sequence data confirms that C6.7 binds near the 
extreme COOH terminus of the peptide chain, which is re- 
tained on the 140-kD fragment. The 140-kD fragment can be 
cleaved to form a  120-kD fragment which lacks the C6.7- 
binding domain but retains the fibrinogen-binding domain. 
The 120-kD fragment can be further cleaved to generate a 70- 
kD fragment which retains the ability to bind type V collagen 
and fibrinogen (5). 
The  140-kD thrombospondin fragment, which lacks the 
heparin-binding site,  retains full haptotactic activity but is 
devoid of chemotactic activity (Figs.  4 and 5).  When this 
fragment is further cleaved to yield a 120-kD fragment, the 
haptotactic activity is totally lost. Since the binding site for 
C6.7, which blocks haptotaxis, is cleaved otf the 140-kD frag- 
ment to yield the 120-kD fragment, it can be concluded that 
the region of thrombospondin essential for haptotactic pro- 
motion  is  located  on  the  COOH  domain  distal  to  the 
chymotrypsin cleavage  site.  This  COOH-terminal  region 
comprises  122  amino acid  residues  starting  with the  se- 
quence  DTNPTRAQGY,  but  lacks  the  RGDA  sequence 
which is located 241  amino acid residues from the COOH 
end of thrombospondin. Synthetic RGD-containing peptides 
failed to significantly inhibit haptotaxis in a dose-dependent 
manner (Table V). The same RGD peptides at 50 lxg/ml ex- 
hibited a remarkable ability to block tumor cell haptotaxis 
on  fibronectin but  not laminin  (Table  V).  As  previously 
reported (23), RGD peptides do not inhibit tumor cell attach- 
ment or spreading on thrombospondin. Thus, the RGD rec- 
ognition sequence does not seem to be directly involved in 
the adhesive and haptotactic interactions of these human tu- 
mor cells with thrombospondin, although an ancillary, in- 
direct role for a cell surface RGD integrin family receptor 
cannot be ruled out. The putative tumor cell surface receptor 
which recognizes the COOH-terminal region of thrombo- 
spondin during haptotaxis remains to be identified. Never- 
theless, it is likely to be similar to the receptor used for tumor 
cell  attachment to  thrombospondin and  thrombospondin- 
mediated platelet aggregation, since C6.7 (but not A2.5) in- 
hibits both activities (7, 23). 
Thrombospondin binds specifically to purified sulfatides 
(galactosylceramide-[Ia]sulfate), and  the  binding  was  in- 
hibited strongly by antibody A2.5  (22).  Thrombospondin 
failed to bind to other purified lipids including cholesterol 
3-sulfate, phospholipids,  neutral glycolipids, and ganglio- 
sides. Fucoidan, a sulfated fucan, and heparin strongly in- 
hibited binding of thrombospondin to sulfatides. Thus, the 
NH2-terminal A2.5-binding domain of thrombospondin con- 
tains an important binding site for sulfated glycoconjugates. 
Thrombospondin-mediated tumor cell spreading is inhibited 
by A2.5, heparin, and fucoidan (23) suggesting that tumor 
cell surface glycoconjugates serve as receptors for spread- 
ing. Autocrine growth-stimulating activity of thrombospon- 
din is also inhibited by heparin and may involve the same 
receptor (17). The same interaction appears to play an impor- 
tant role in tumor cell chemotaxis. A2.5, heparin, and fucoi- 
dan all inhibit chemotaxis but not haptotaxis (Tables III and 
IV). The 140- and 120-kD fragments of  thrombospondin pro- 
duced by thrombin, trypsin, or chymotrypsin, which lack 
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these results are in keeping with the location of a specific site 
on  the  NH2-terminus  of thrombospondin which  mediates 
chemotaxis. This site must be exposed on the soluble throm- 
bospondin molecule. 
In the thrombospondin chemotactic assay, binding of the 
soluble thrombospondin to the filter to indirectly generate a 
haptotactic gradient was negligible as determined by labeled 
thrombospondin binding to filters.  Furthermore,  if throm- 
bospondin chemotaxis was, in fact, indirectly mediated hap- 
totaxis,  C6.7,  A2.5,  heparin,  fucoidan,  and protease frag- 
ments retaining or lacking the heparin-binding domain would 
not exhibit the markedly differential inhibition of chemotaxis 
vs.  haptotaxis shown in Tables III and IV,  and in Fig.  5. 
Roberts et al. (23) and Varani et al. (31) demonstrated that 
thrombospondin can mediate  tumor cell  adhesion.  Tumor 
cells encounter thrombospondin at many stages of tumor in- 
vasion, extravasation, and metastasis.  The present data sug- 
gest that the role played by thrombospondin is more than just 
as  an  adhesion  protein.  Thrombospondin  is  present  in 
plasma in a low concentration (20 ng/ml). However, in areas 
of platelet stimulation, such as in the proximity of a vessel 
injury,  it can  reach  chemotactically  active  concentrations 
(>15 ~tg/ml)  (15). Thus, thrombospondin can potentially at- 
tract circulating tumor cells toward a site of endothelial in- 
jury. Once they arrive at this site, the tumor cells can adhere 
to  the  insolubilized  thrombospondin  present  on  the  en- 
dothelial cell surface or imbedded in the exposed extracellu- 
lar matrix. Here the directional migration can be stimulated 
by a haptotactic mechanism. 
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